Trump’s Push for Lower Drug Prices Meets Resistance (Image Credits: Unsplash)
Senators led by Bernie Sanders released a pointed report highlighting persistent increases in U.S. prescription drug costs, even as the Trump administration touted agreements with major pharmaceutical firms. The findings, timed ahead of a key Senate hearing, underscore tensions between White House initiatives and industry practices. Patients continue to face steep bills for vital treatments, raising doubts about the real-world effects of these high-profile deals.[1]
Trump’s Push for Lower Drug Prices Meets Resistance
The Trump administration secured what it described as groundbreaking “most favored nation” agreements with several drugmakers, aiming to align U.S. prices with those in other wealthy nations. President Trump repeatedly emphasized these pacts as a pathway to dramatic reductions in medication costs for Americans. Yet the Senate Democrats’ analysis revealed a different reality on the ground.
Companies involved in these deals posted record profits last year, totaling $177 billion in 2025, a sharp rise from the prior year’s $107 billion. The report scrutinized firms that had inked such agreements, noting they continued business as usual for many products outside the specific terms. This selective approach left broad swaths of the market untouched by promised relief.[1]
Report Uncovers Widespread List Price Increases
Senate staff examined pricing data and found that signatory companies hiked list prices on hundreds of medications across categories like cancer therapies and gene treatments. New drugs hit the market with eye-watering annual costs averaging $353,000. These escalations persisted even during negotiations or after deals were finalized.
The document spotlighted how higher list prices bolstered what manufacturers charge insurers, while discounts on platforms like TrumpRx.gov targeted cash-paying customers. Such mechanisms echoed existing tools like GoodRx but failed to address systemic pricing pressures. Overall brand-name list prices dipped slightly this year for the first time, largely crediting prior Biden-era Medicare negotiations rather than recent pacts.[1]
Key Drugs Hit Hard: A Closer Look
Blockbuster medications bore the brunt of these adjustments, with familiar names seeing notable jumps. Cancer and chronic disease patients felt the pinch most acutely. International comparisons painted a stark picture of U.S. pricing outliers.
| Drug | Company | U.S. Annual List Price (Post-Hike) | Example Foreign Price |
|---|---|---|---|
| Keytruda (cancer) | Merck | $210,000 (up 6%) | Japan: $37,900 |
| Kesimpta (MS) | Novartis | $141,000 (up $10,500) | Germany: $17,300 |
| Opdivo (immunotherapy) | Bristol Myers Squibb | $260,000 (up 4%) | France: $90,300 |
| Vizimpro (lung cancer) | Pfizer | $208,000 (up 5%) | N/A |
- Zolgensma (Novartis gene therapy): Rose nearly $200,000 to over $2.5 million per course.
- Itvisma (Novartis gene therapy): Launched at $2.59 million.
- Inlexzo (Johnson & Johnson cancer drug): Debuted at about $1 million annually.
- Emrelis (AbbVie cancer drug): Priced at $719,000.
- Datroway (AstraZeneca cancer drug): Set at $419,000.
White House and Experts Weigh In on the Deals’ Limits
A White House spokesperson dismissed the report’s focus, arguing that list prices bore little relation to what patients actually paid at pharmacies. Kush Desai highlighted discounts available through TrumpRx as evidence of progress. Still, critics pointed to opaque terms that shielded companies from portfolio-wide cuts.
Health policy expert Stacie Dusetzina of Vanderbilt University called the announcements frustrating due to missing transparency, suggesting they primarily aided drug firms. Antonio Ciaccia, CEO of drug pricing tracker 46brooklyn, noted the deals covered select products only, allowing hikes elsewhere. Pharmaceutical giants like Merck, Novartis, and Pfizer offered no immediate response to the findings.[1]
Key Takeaways:
- All examined drugmakers had Trump deals but raised prices on hundreds of drugs anyway.
- New therapies launched at median $353,000 yearly, with gene treatments exceeding $2 million.
- U.S. prices dwarf international rates, fueling calls for broader reforms.
As the Senate prepares for its hearing, the report amplifies calls for enforceable measures to curb pricing power. Patients navigating these costs deserve clarity on whether voluntary pacts deliver lasting savings. What steps should lawmakers take next to bridge the gap between promises and pharmacy receipts? Share your thoughts in the comments.
